Jump to content

3,4-Methylenedioxy-N-isopropylamphetamine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Fswitzer4 (talk | contribs) at 14:36, 29 May 2020 (Added FDA UNII). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

3,4-Methylenedioxy-N-isopropylamphetamine
Names
IUPAC name
(2-Benzo[1,3]dioxol-5-yl-1-methylethyl)isopropylamine
Other names
3,4-Methylenedioxy-N-isopropylamphetamineamine
3,4-Methylenedioxy-1-(alpha-methyl-amino-isopropyl)-ethane
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C13H19NO2/c1-9(2)14-10(3)6-11-4-5-12-13(7-11)16-8-15-12/h4-5,7,9-10,14H,6,8H2,1-3H3
    Key: XKEVWMVUIDDRMC-UHFFFAOYSA-N
  • C1=C2C(=CC=C1CC(C)NC(C)C)OCO2
Properties
C13H19NO2
Molar mass 221.300 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

3,4-Methylenedioxy-N-isopropylamphetamine (MDIP, MDIPA) is a psychoactive drug of the phenethylamine and amphetamine chemical classes which acts as an entactogen, psychedelic, and stimulant. It is the N-isopropyl analogue of 3,4-methylenedioxyamphetamine (MDA). MDIP was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 250 mg.[1] MDIP produces a mild threshold. Very little is known about the pharmacology, pharmacokinetics, effects, and toxicity of MDIP.

References

Template:PiHKAL